Highlights

Prolor Biotech Downgraded by Summer Street (PBTH)

 Source: ABMN Staff   |   Publish date: Mon, 12 Nov 11:58   |    >> Read article in News website

Prolor Biotech (NASDAQ: PBTH) was downgraded by research analysts at Summer Street from a “buy” rating to a “sell” rating in a report released on Monday.

Prolor Biotech traded down 3.16% on Monday, hitting $4.60. Prolor Biotech has a 52-week low of $3.11 and a 52-week high of $6.69. The company’s market cap is $291.7 million.

Several other analysts have also recently commented on the stock. Analysts at Oppenheimer initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 29th. They set an “outperform” rating and a $7.00 price target on the stock. Analysts at Jefferies Group initiated coverage on shares of Prolor Biotech in a research note to investors on Wednesday, August 22nd. They set a “buy” rating and a $8.00 price target on the stock.

Prolor Biotech, Inc. (Prolor), formerly Modigene Inc. is a development-stage biopharmaceutical company, utilizing technology to develop versions of therapeutic proteins.

Share this

  Be the first to like this.
 


 

4180  2954  630  398 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 SPY 196.43+1.50 
 F 13.78-0.62 
 DRYS 1.52-0.48 
 PBR 12.93+0.82 
 VXX 33.17-0.31 
 MSFT 46.13+1.11 
 EWZ 41.57+1.73 
 AAPL 105.22+0.39 
 EEM 41.02+0.29 
 QQQ 98.62+0.80 
Partners & Brokers